New data from Biogen reveals higher Spinraza doses may enhance motor function in SMA patients. Read more here.

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

He emphasized that residential investment will be crucial for overall GDP growth, as current CapEx spending in the US is ...